Aerie Pharmaceuticals, Inc. AERI
Set alert
15.25 0.00 0.00%
At close · Nov 18
15.24 Day range 15.25
52-week range unavailable
- Open
- 15.24
- Prev close
- 15.25
- Mkt cap
- 753.62M
- Vol
- 1.22M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 15.24
- High
- 15.25
- Forward P/E
- -13.86
- Beta
- -0.06
- Short ratio
- 1.91
- Inst. own
- 102.99%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2022
- 50-d avg
- 15.19
- 200-d avg
- 10.24
- 1y target
- 15.35
2Y chart
Events in this range
- Nov 4, 2021Earnings: —; estimate -0.62; surprise —%
- Feb 24, 2022Earnings: —; estimate -0.68; surprise —%
- May 5, 2022Earnings: —; estimate -0.65; surprise —%
- Aug 4, 2022Earnings: —; estimate -0.52; surprise —%
- Aug 23, 2022Downgrade: Cantor Fitzgerald · Overweight → Neutral
- Aug 23, 2022Downgrade: Needham · Buy → Hold
- Aug 23, 2022Downgrade: Stifel · Buy → Hold
- Aug 24, 2022Downgrade: HC Wainwright & Co. · Buy → Neutral
- Aug 24, 2022Downgrade: Truist Securities · Buy → Hold
- Aug 29, 2022Downgrade: Citigroup · Buy → Neutral
- Nov 3, 2022Earnings: —; estimate -0.42; surprise —%
Signals (25)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Sep 8, 2022 | 4 years ago |
| RSI: Overbought | Aug 23, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 8, 2022 | 4 years ago |
| RSI: Overbought | Aug 8, 2022 | 4 years ago |
| SMA: Bullish | Aug 4, 2022 | 4 years ago |
| SMA: Bearish | Jul 29, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 15, 2022 | 4 years ago |
| SMA: Bullish | Jun 23, 2022 | 4 years ago |
| SMA: Bearish | Jun 22, 2022 | 4 years ago |
| SMA: Bullish | Jun 21, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 6, 2022 | 4 years ago |
| MACD: Sell Signal | May 24, 2022 | 4 years ago |
| MACD: Buy Signal | May 17, 2022 | 4 years ago |
| SMA: Bearish | Apr 21, 2022 | 4 years ago |
| SMA: Bullish | Apr 13, 2022 | 4 years ago |
| SMA: Bearish | Apr 11, 2022 | 4 years ago |
| MACD: Sell Signal | Apr 1, 2022 | 4 years ago |
| SMA: Bullish | Feb 25, 2022 | 4 years ago |
| MACD: Buy Signal | Feb 25, 2022 | 4 years ago |
| RSI: Oversold | Feb 23, 2022 | 4 years ago |
| MACD: Sell Signal | Feb 17, 2022 | 4 years ago |
| MACD: Buy Signal | Jan 3, 2022 | 4 years ago |
| MACD: Sell Signal | Dec 28, 2021 | 4 years ago |
| RSI: Oversold | Dec 27, 2021 | 4 years ago |
| MACD: Buy Signal | Dec 22, 2021 | 4 years ago |
Key statistics
- Market cap
- 753.62M
- Enterprise value
- 918.14M
- Trailing P/E
- 0.00
- Forward P/E
- -13.86
- PEG ratio
- 0.07
- Price / sales
- 3.52
- Price / book
- 0.00
- EPS (TTM)
- -1.47
- Beta
- -0.06
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -17.09%
- Revenue (TTM)
- 213.94M
- Revenue growth
- 23.30%
- Free cash flow
- 1.83M
- Total cash
- 172.46M
- Total debt
- 336.99M
- Return on equity
- 0.00%
- Shares outstanding
- 49.42M
- Short % of float
- 3.13%
- 50-day average
- 15.19
- 200-day average
- 10.24
Analyst view
Consensus: hold
Hold
Price target (mean) 15.35 +0.7% upside
Now 15.25
- Target (low)
- 6.00
- Target (mean)
- 15.35
- Target (high)
- 25.00
Ratings (0m) 10 9 buy · 1 hold · 0 sell
- Strong buy3
- Buy6
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2022
Expected Nov 3, 2022. Consensus EPS estimate -0.43.
Financials — quick view
AERI Revenue — quarterly 36.13M
AERI Net income — quarterly -26.83M
AERI EPS — quarterly -0.56
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2022 | Sep 1, 2022 | -0.42 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -0.52 | — | — | — |
| May 5, 2022 | Mar 1, 2022 | -0.65 | — | — | — |
| Feb 24, 2022 | Dec 1, 2021 | -0.68 | — | — | — |
| Nov 4, 2021 | Sep 1, 2021 | -0.62 | — | — | — |
| Aug 4, 2021 | Jun 1, 2021 | -0.65 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 29, 2022 | Citigroup | down | Buy | Neutral |
| Aug 24, 2022 | Truist Securities | down | Buy | Hold |
| Aug 24, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Aug 23, 2022 | Stifel | down | Buy | Hold |
| Aug 23, 2022 | Needham | down | Buy | Hold |
| Aug 23, 2022 | Cantor Fitzgerald | down | Overweight | Neutral |
About Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- aeriepharma.com
News
- Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical Business
- Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates
- Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results
- Add These 4 Top-Ranked Liquid Stocks For Healthy Gains
- 5 Small Hidden Gems Flying High Despite Market's Bloodbath
- 5 Stocks to Bet on in an Innovation-Driven Drug Industry
- Are Medical Stocks Lagging Aerie Pharmaceuticals (AERI) This Year?
- AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI
- Is Aerie Pharmaceuticals (AERI) Stock Outpacing Its Medical Peers This Year?
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AERI, ECOM, PFS, LBAI
Your note
Sign in to keep a note on AERI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CALABRESE JEFFREY | Officer | Stock Award(Grant) | Jun 30, 2022 | 19,295 |
| CROARKIN RICHARD | Director | Stock Award(Grant) | Jun 8, 2022 | 16,095 |
| DU TOIT MICHAEL | Director | Stock Award(Grant) | Jun 8, 2022 | 16,095 |
| GRYSKA DAVID W | Director | Stock Award(Grant) | Jun 8, 2022 | 13,491 |
| KOPCZYNSKI CASEY C | Officer | Stock Award(Grant) | Mar 17, 2022 | 280,244 |
| LANG PETER FREDERICK | Chief Financial Officer | Stock Award(Grant) | Mar 17, 2022 | 46,297 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 9.82% | 4,855,005 | 74.04M | Sep 29, 2022 |
| Blackrock Inc. | 7.17% | 3,544,947 | 54.06M | Sep 29, 2022 |
| Vanguard Group, Inc. (The) | 4.94% | 2,441,120 | 37.23M | Sep 29, 2022 |
| UBS Group AG | 4.87% | 2,405,832 | 36.69M | Sep 29, 2022 |
| Jefferies Group LLC | 4.78% | 2,361,000 | 36.01M | Sep 29, 2022 |
| Water Island Capital, LLC | 4.21% | 2,082,516 | 31.76M | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.92% | 1,445,441 | 22.04M | Jun 29, 2022 |
| Arbitrage Fund | 2.30% | 1,136,386 | 17.33M | Aug 30, 2022 |
| iShares Russell 2000 ETF | 2.11% | 1,044,068 | 15.92M | Sep 29, 2022 |
| Vanguard Extended Market Index Fund | 1.32% | 650,497 | 9.92M | Jun 29, 2022 |
| Columbia Fds Var Ser Tr II-Columbia Var Port-Overseas Core Fd | 1.09% | 540,033 | 8.24M | Jun 29, 2022 |
| IndexIQ Tr-IQ Merger Arbitrage ETF | 0.94% | 463,978 | 7.08M | Oct 30, 2022 |